L. Duthoit

Validité d’un nouvel outil de dépistage de la somnolence diurne excessive : le questionnaire de somnolence de Yaoundé

Massongo Massongo, L. Duthoit, Adamou Dodo Balkissou, Stéphanie Fry et autres

Cameroun, fr (code pays fourni par la source)

The expanded French compassionate programme for elexacaftor–tezacaftor–ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study

Pierre‐Régis Burgel, Isabelle Sermet‐Gaudelus, Emmanuelle Girodon, I. Durieu et autres

fr, re (code pays fourni par la source)

WS16.05 Changes in Aspergillus parameters and antifungal prescriptions in adults with cystic fibrosis treated by elexacaftor/tezacaftor/ivacaftor

L. Flan, C. Audousset, T. Pérez, Anne Prévötat et autres

fr (code pays fourni par la source)

Validity of a novel excessive daytime sleepiness’ screening stool : the Yaoundé Sleepiness Score.

Massongo Massongo, L. Duthoit, Adamou Dodo Balkissou, Marie Elisabeth Ngah Komo et autres

Background The subjective assessment of excessive daytime sleepiness (EDS) using Epworth sleepiness scale (ESS) has shown some limits. This study aimed to assess the validity of the Yaoundé Sleepiness Scale (YSS), a new tool for EDS screening, using ESS as reference. Methodology …

Cameroun (code pays fourni par la source)

P122 Immunization coverage and new issues of it at the age of novel CFTR modulator therapies in adults with cystic fibrosis

Macha Tétart, Olivier Le Rouzic, T. Pérez, L. Duthoit et autres

fr (code pays fourni par la source)

P336 Evolution of the body composition of people with cystic fibrosis 6 months after the introduction of treatment with exacaftor/tezacaftor/ivacaftor (ETI)

H. Bernard, Macha Tétart, L. Duthoit, T. Pérez et autres

fr (code pays fourni par la source)

Évaluation des composantes physique et affective de la dyspnée persistant au-delà de 3 mois d’une infection Covid

L. Martinache, S. Fry, T. Perez, J.-F. Bervar et autres

fr (code pays fourni par la source)

Évolution de la composition corporelle des patients atteints de mucoviscidose à 6 mois de l’introduction d’un traitement par exacaftor-tezacaftor-ivacaftor

H. Bernard, H. Lecomte, I. Soarez, A.M. Halm et autres

fr (code pays fourni par la source)

Assessment of pulmonary arterial circulation 3 months after hospitalization for SARS-CoV-2 pneumonia: Dual-energy CT (DECT) angiographic study in 55 patients

Martine Rémy-Jardin, L. Duthoit, T. Pérez, Paul Felloni et autres

Background During COVID-19, the main manifestations of the disease are not only pneumonia but also coagulation disorders. The purpose of this study was to evaluate pulmonary vascular abnormalities 3 months after hospitalization for SARS-CoV-2 pneumonia in patients with persistent respiratory symptoms. Methods …

fr (code pays fourni par la source)

Respiratory support in patients with COVID-19 (outside intensive care unit). A position paper of the Respiratory Support and Chronic Care Group of the French Society of Respiratory Diseases

Claudio Rabec, Jésus Gonzalez‐Bermejo, M. Mercy, L. Grassion et autres

fr, us, bg, ch (code pays fourni par la source)

Long-term evaluation of home-based pulmonary rehabilitation in patients with fibrotic idiopathic interstitial pneumonias

B. Wallaert, L. Duthoit, Élodie Drumez, Hélène Behal et autres

Background Few studies have examined the benefits of pulmonary rehabilitation in patients with fibrotic idiopathic pulmonary pneumonia (f-IIP). Here, we report the results of an observational study in routine clinical practice of home-based pulmonary rehabilitation for f-IIP patients. Methods A total of …

fr, us (code pays fourni par la source)